^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Solid Tumor
    Drug:AFNT-211 (TCR modulator, KRAS G12V inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

    Excerpt:
    ...Confirmed KRAS G12V mutational status and HLA-A*11:01 allele 2....
    Trial ID:
    NCT06105021
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2023
    Title:

    AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors.

    Published date:
    05/25/2023
    Excerpt:
    AFNT-211 was assessed for efficacy in vitro against a panel of KRASG12V-expressing tumor cell lines and in vivo using human xenograft mouse models….Coculture of AFNT-211 with a panel of KRASG12V-expressing tumor cell lines led to significant effector cytokine secretion, T cell proliferation, and tumor cell killing....Potent anti-tumor response was observed in vivo in a mouse xenograft model….
    DOI:
    10.1200/JCO.2023.41.16_suppl.2543